Ceftolozane/tazobactam

(Zerbaxa®)

Zerbaxa®

Drug updated on 11/13/2023

Dosage FormInjection (intravenous; ceftolozane/tazobactam: 1 g/0.5 g)
Drug ClassMultiple
Ongoing and
Completed Studies
ClinicalTrials.gov

Indication

  • Indicated in combination with metronidazole in patients 18 years or older for the treatment of complicated intra-abdominal infections (cIAI) caused by designated susceptible microorganisms.
  • Indicated in patients 18 years or older for the treatment of complicated urinary tract infections (cUTI) (including pyelonephritis) caused by designated susceptible microorganisms.
  • Indicated in patients 18 years or older for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (HABP/VABP) caused by designated susceptible microorganisms.

Product Monograph / Prescribing Information

Document TitleYearSource
Zerbaxa (ceftolozane/tazobactam) Prescribing Information.2022Merck Sharp & Dohme LLC, Rahway, NJ

Systematic Reviews / Meta-Analyses

Document TitleYearSource
Comparing novel antibiotics and carbapenems for complicated intra-abdominal infections: A systematic review and meta-analysis of randomized controlled trials.2023International Journal of Antimicrobial Agents
A Meta-Analysis on Clinical Outcomes of Ceftolozane versus Piperacillin in Combination with Tazobactam in Patients with Complicated Urinary Tract Infections.2022BioMed Research International
Choosing optimal antibiotics for the treatment of patients infected with Enterobacteriaceae: a network meta-analysis and cost-effectiveness analysis.2021Frontiers in Pharmacology
Real-world use of ceftolozane/tazobactam: a systematic literature review.2021Antimicrobial Resistance and Infection Control
Systematic review of the stability of antimicrobial agents in elastomeric devices for outpatient parenteral antimicrobial therapy services based on NHS Yellow Cover Document standards.2021European Journal of Hospital Pharmacy
Ceftolozane/Tazobactam for Resistant Drugs Pseudomonas aeruginosa Respiratory Infections: A Systematic Literature Review of the Real-World Evidence.2021Life
Systematic literature review of real-world evidence of ceftolozane/tazobactam for the treatment of respiratory infections.2021Infectious Disease and Therapy
The use of ceftolozane-tazobactam in the treatment of complicated intra-abdominal infections and complicated urinary tract infections—A meta-analysis of randomized controlled trials.2020International Journal of Antimicrobial Agents
Clinical cure rate and cost-effectiveness of carbapenem-sparing beta-lactams vs. meropenem for Gram-negative infections: a systematic review, meta-analysis, and cost-effectiveness analysis.2020International Journal of Antimicrobial Agents
Fluoroquinolones for the treatment of urinary tract infection: a review of clinical effectiveness, cost effectiveness, and guidelines. 2019CADTH
Antimicrobial prescribing: ceftolozane with tazobactam for treating hospital-acquired pneumonia, including ventilator-associated pneumonia.2019NICE

Clinical Practice Guidelines

Document TitleYearSource
EAU guidelines on urology infections.2023European Association of Urology